Form 4: Liquidia CEO Roger Jeffs Executes Stock Sale Plan

Liquidia Corporation CEO Roger Jeffs sold 75,000 shares of common stock over three days in May 2026 under a pre-arranged 10b5-1 trading plan.

Summary

• CEO Roger Jeffs sold a total of 75,000 shares of Liquidia Corp (LQDA) common stock between May 13 and May 15, 2026.
• The sales were executed in three equal tranches of 25,000 shares each.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on November 5, 2025.
• The weighted average sale prices were $56.2851, $58.6226, and $57.0429 per share respectively.
• Following these transactions, the reporting person retains beneficial ownership of 1,198,095 shares held via Serendipity BioPharma LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were pre-planned and represent standard executive financial management rather than a reaction to company-specific news.

Positives

• The sales were executed pursuant to a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell stock without concerns regarding insider trading.

Negatives

• The sale of 75,000 shares represents a reduction in the CEO's direct and indirect equity stake in the company.

Risks

• Continued selling by executive leadership can sometimes be perceived negatively by retail investors, potentially impacting short-term stock price sentiment.

Future Outlook

No forward-looking guidance regarding company operations or financial performance was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are routine corporate governance events and generally do not signal a change in the company's fundamental outlook or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives at publicly traded biotech firms to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the systematic nature of the sales suggests personal financial planning rather than a lack of confidence in the company.

Next Steps

• Continued monitoring of future Form 4 filings for further activity under the established 10b5-1 plan.

Key Dates

Keywords

Liquidia, LQDA, Insider Trading, Form 4, Roger Jeffs, Biopharma, 10b5-1